Application of Biolayer Interferometry (BLI) for Studying Protein-Protein Interactions in Transcription
July 26th, 2019
13.8K views
Interactions of transcription factors (TFs) with the RNA polymerase are usually studied using pulldown assays. We apply a Biolayer Interferometry (BLI) technology to characterize the interaction of GrgA with the chlamydial RNA polymerase. Compared to pulldown assays, BLI detects real-time association and dissociation, offers higher sensitivity, and is highly quantitative.
Overview
This study utilizes biolayer interferometry (BLI) to investigate the interaction between GrgA and chlamydial RNA polymerase. BLI offers advantages over traditional pulldown assays by providing real-time data on association and dissociation, along with enhanced sensitivity and quantitative analysis.
Key Study Components
Area of Science
- Biochemistry
- Molecular Biology
- Transcription Regulation
Background
- Protein-protein interactions are crucial in transcription processes.
- Traditional methods like pulldown assays have limitations in real-time analysis.
- Biolayer interferometry (BLI) is a newer technology that addresses these limitations.
- BLI provides quantitative kinetic parameters indicative of interaction mechanisms.
Purpose of Study
- To characterize the interaction of GrgA with chlamydial RNA polymerase.
- To demonstrate the advantages of BLI over traditional methods.
- To provide insights into the dynamics of transcription factor interactions.
Methods Used
- Biolayer interferometry (BLI) technology.
- Real-time monitoring of protein interactions.
- Quantitative analysis of association and dissociation rates.
- Comparison with traditional pulldown assays.
Main Results
- BLI successfully detected real-time interactions between GrgA and RNA polymerase.
- Results showed higher sensitivity compared to pulldown assays.
- Quantitative kinetic parameters were generated, revealing interaction mechanisms.
- The study highlights the ease of learning and using BLI technology.
Conclusions
- BLI is a powerful tool for studying protein-protein interactions in transcription.
- It provides real-time data and quantitative insights that traditional methods lack.
- The findings support the use of BLI in future transcription studies.
Frequently Asked Questions
What is biolayer interferometry?
Biolayer interferometry (BLI) is a technology used to measure the interactions between biomolecules in real-time.
How does BLI differ from traditional pulldown assays?
BLI provides real-time data on association and dissociation, while pulldown assays are purely quantitative.
What are the advantages of using BLI?
BLI offers higher sensitivity, quantitative analysis, and the ability to monitor interactions in real-time.
Is BLI difficult to learn?
No, BLI technology is not difficult to learn, especially with access to the necessary instruments and software.
What types of interactions can BLI measure?
BLI can measure various biomolecular interactions, including protein-protein, protein-DNA, and protein-ligand interactions.
Can BLI be used for other applications beyond transcription studies?
Yes, BLI is versatile and can be applied in various fields, including drug discovery and diagnostics.
Executive Industry Relevance
Biolayer interferometry (BLI) addresses a key challenge in early discovery by enabling real-time, quantitative analysis of protein-protein interactions critical for target validation in transcription regulation. Its ability to detect binding events missed by traditional pulldown assays increases predictive confidence in mechanistic de-risking of transcription factor pathways. This supports informed go/no-go decisions in lead identification and preclinical model selection for antimicrobial targets.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by confirming transcription factor interactions with sigma factors in pathogenic bacteria.
- Operational Value: Provides quantitative kinetic parameters (association/dissociation rates) that clarify interaction mechanisms and reduce mechanistic ambiguity.
- Predictive Value: Detects low-affinity or transient interactions missed by endpoint assays, improving target confidence and portfolio triage for antimicrobial programs.
Screening & Assay Development
- Assay Readiness: Generates reproducible, real-time binding curves suitable for standardization across compound screening campaigns.
- Quantitative Output: Delivers kinetic constants (kon, koff, KD) that enable rank-ordering of ligands or mutants in lead optimization.
- Scalability: Supports multi-concentration analysis using regeneration cycles, facilitating medium-throughput profiling of interaction networks.
Translational & Preclinical Research
- Disease Relevance: Characterizes interactions in Chlamydia, an obligate intracellular pathogen, supporting preclinical validation of transcription-related virulence mechanisms.
- Translational Continuity: Links molecular interaction data to functional outcomes in gene expression, enabling biomarker-aligned target validation.
- Risk-Adjusted Advancement: Supports go/no-go decisions by quantifying binding strength and specificity early in the discovery funnel.
Pipeline & Workflow Integration
BLI fits within the discovery continuum from target engagement screening to lead optimization, providing mechanistic insights that inform downstream preclinical validation of transcription-modulating therapeutics.
- Discovery Biology: Supports hypothesis testing of transcription factor networks by delivering real-time, quantitative interaction data essential for pathway clarification.
- Screening: Enables assay readiness through reproducible, label-free detection of biomolecular interactions with defined kinetic outputs.
- Analytics: Generates association/dissociation sensorgrams and fitted KD values that allow objective comparison of binding conditions across analyte concentrations.
- Translational Research: Connects molecular interaction kinetics to functional transcriptional regulation in disease-relevant systems like Chlamydia.
- Enterprise Reuse: Represents a portable, label-free platform applicable across multiple target classes beyond transcription, supporting shared service lab models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by revealing real-time binding kinetics and detecting interactions undetectable by pulldown assays.
- Operational Value: Delivers standardized, reproducible workflows with minimal sample consumption and no need for radioactive or fluorescent labels.
- Strategic Value: Improves capital efficiency by reducing false positives in early screening and enabling data-driven prioritization of high-confidence targets.
- Portfolio Impact: Supports risk-adjusted advancement by providing quantitative binding data that inform structure-activity relationships and lead optimization.
Implementation Considerations
- Requires expertise in protein purification, His-tagging, and biosensor handling to ensure proper ligand immobilization and analyte delivery.
- Dependent on access to a BLI instrument (e.g., Blitz system) and associated software for real-time data acquisition and kinetic fitting.
- Necessitates cross-team standardization of buffer conditions, dialysis protocols, and baseline correction steps to ensure data comparability.
- Involves adaptation considerations when applying to different model systems, particularly regarding ligand stability and surface regeneration efficiency.
- Limited by the need for optimized immobilization density to avoid mass transport artifacts and ensure accurate kinetic modeling.
Biopharma FAQs
Why does real-time association and dissociation matter for target validation?
Real-time association and dissociation measurements enable calculation of kinetic parameters (kon, koff, KD) that reveal binding mechanism and affinity, which are critical for assessing target engagement strength and selectivity in early discovery.
How does isolating the independent variable (ligand concentration) support the discovery pipeline?
Varying ligand concentration while holding analyte constant allows determination of concentration-dependent binding responses, enabling accurate KD calculation and structure-activity relationship modeling in lead optimization.
What do quantitative dependent variable measurements (binding response over time) enable?
Time-dependent binding response data generate sensorgrams that are fitted to extract association and dissociation rates, providing mechanistic insights into interaction stability and complex formation.
Why do replication requirements matter for cross-functional collaboration?
Replicating binding experiments across analyte concentrations ensures data reliability and reproducibility, which are essential for transferring assay results between discovery biology, medicinal chemistry, and preclinical teams.
What statistical analysis capabilities are required before implementing BLI in a discovery workflow?
The ability to perform reference subtraction, baseline correction, and 1:1 kinetic fitting is required to extract accurate kon, koff, and KD values from raw sensorgram data for comparative analysis across experimental conditions.
Chapters in this video
0:04
Title
0:59
Biosensor Hydration and Assay Set-Up
2:51
Loading of Ligand onto Biosensor and Washing Away Additional Ligand
3:43
Association of Analyte to Ligand and Dissociation of Analyte from Ligand
5:41
Results: A 28 Amino Acid Middle Region of GrgA Binds σ28 In Vitro
6:45
Conclusion
